Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study
Paolo Corradini, Chiara Agrati, Giovanni Apolone, Alberto Mantovani, Diana Giannarelli, Vincenzo Marasco, Veronica Bordoni, Alessandra Sacchi, Giulia Matusali, Carlo Salvarani, Pier Luigi Zinzani, Renato Mantegazza, Fabrizio Tagliavini, Maria Teresa Lupo Stanghellini, Fabio Ciceri, Silvia Damian, Antonio Uccelli, Fausto Baldanti, Giulia Piaggio, Gennaro Ciliberto, Franco Locatelli, Valentina Sinno, Massimo Costantini, Giovanni Apolone, Alberto Mantovani, Massimo Costantini, Nicola Silvestris, Giovanni Apolone, Gennaro Ciliberto, Massimo Costantini, Franco Locatelli, Alberto Mantovani, Angelo Paradiso, Carlo Salvarani, Fabrizio Tagliavini, Antonio Uccelli, Paolo Corradini, Gennaro Ciliberto, Carlo Salvarani, Antonio Uccelli, Renato Mantegazza, Roberta Mortarini, Cristina Tresoldi, Laura Conti, Chiara Mandoj, Michela Lizier, Stefania Croci, Fausto Baldanti, Vito Michele Garrisi, Fulvio Baggi, Tiziana Lazzarotto, Francesca Bonifazi, Fulvia Pimpinelli, Concetta Quintarelli, Rita Carsetti, Enrico Girardi, Aurora Bettini, Concetta Castilletti, Eleonora Cimini, Rita Casetti, Francesca Colavita, Flavia Cristofanelli, Massimo Francalancia, Simona Gili, Delia Goletti, Giulia Gramigna, Germana Grassi, Daniele Lapa, Sara Leone, Davide Mariotti, Giulia Matusali, Silvia Meschi, Stefania Notari, Enzo Puro, Marika Rubino, Alessandra Sacchi, Eleonora Tartaglia, Paolo Corradini, Silvia Damian, Vincenzo Marasco, Filippo de Braud, Maria Teresa Lupo Stanghellini, Lorenzo Dagna, Francesca Rita Ogliari, Massimo Filippi (2022). Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. , 76(3), DOI: https://doi.org/10.1093/cid/ciac404.
Article11 days agoHumoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study
Paolo Corradini, Chiara Agrati, Giovanni Apolone, Alberto Mantovani, Diana Giannarelli, Vincenzo Marasco, Veronica Bordoni, Alessandra Sacchi, Giulia Matusali, Carlo Salvarani, Pier Luigi Zinzani, Renato Mantegazza, Fabrizio Tagliavini, Maria Teresa Lupo Stanghellini, Fabio Ciceri, Silvia Damian, Antonio Uccelli, Fausto Baldanti, Giulia Piaggio, Gennaro Ciliberto, Franco Locatelli, Valentina Sinno, Massimo Costantini, Giovanni Apolone, Alberto Mantovani, Massimo Costantini, Nicola Silvestris, Giovanni Apolone, Gennaro Ciliberto, Massimo Costantini, Franco Locatelli, Alberto Mantovani, Angelo Paradiso, Carlo Salvarani, Fabrizio Tagliavini, Antonio Uccelli, Paolo Corradini, Gennaro Ciliberto, Carlo Salvarani, Antonio Uccelli, Renato Mantegazza, Roberta Mortarini, Cristina Tresoldi, Laura Conti, Chiara Mandoj, Michela Lizier, Stefania Croci, Fausto Baldanti, Vito Michele Garrisi, Fulvio Baggi, Tiziana Lazzarotto, Francesca Bonifazi, Fulvia Pimpinelli, Concetta Quintarelli, Rita Carsetti, Enrico Girardi, Aurora Bettini, Concetta Castilletti, Eleonora Cimini, Rita Casetti, Francesca Colavita, Flavia Cristofanelli, Massimo Francalancia, Simona Gili, Delia Goletti, Giulia Gramigna, Germana Grassi, Daniele Lapa, Sara Leone, Davide Mariotti, Giulia Matusali, Silvia Meschi, Stefania Notari, Enzo Puro, Marika Rubino, Alessandra Sacchi, Eleonora Tartaglia, Paolo Corradini, Silvia Damian, Vincenzo Marasco, Filippo de Braud, Maria Teresa Lupo Stanghellini, Lorenzo Dagna, Francesca Rita Ogliari, Massimo Filippi (2022). Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. , 76(3), DOI: https://doi.org/10.1093/cid/ciac404.
Article11 days agoHumoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study
Paolo Corradini, Chiara Agrati, Giovanni Apolone, Alberto Mantovani, Diana Giannarelli, Vincenzo Marasco, Veronica Bordoni, Alessandra Sacchi, Giulia Matusali, Carlo Salvarani, Pier Luigi Zinzani, Renato Mantegazza, Fabrizio Tagliavini, Maria Teresa Lupo Stanghellini, Fabio Ciceri, Silvia Damian, Antonio Uccelli, Fausto Baldanti, Giulia Piaggio, Gennaro Ciliberto, Franco Locatelli, Valentina Sinno, Massimo Costantini, Giovanni Apolone, Alberto Mantovani, Massimo Costantini, Nicola Silvestris, Giovanni Apolone, Gennaro Ciliberto, Massimo Costantini, Franco Locatelli, Alberto Mantovani, Angelo Paradiso, Carlo Salvarani, Fabrizio Tagliavini, Antonio Uccelli, Paolo Corradini, Gennaro Ciliberto, Carlo Salvarani, Antonio Uccelli, Renato Mantegazza, Roberta Mortarini, Cristina Tresoldi, Laura Conti, Chiara Mandoj, Michela Lizier, Stefania Croci, Fausto Baldanti, Vito Michele Garrisi, Fulvio Baggi, Tiziana Lazzarotto, Francesca Bonifazi, Fulvia Pimpinelli, Concetta Quintarelli, Rita Carsetti, Enrico Girardi, Aurora Bettini, Concetta Castilletti, Eleonora Cimini, Rita Casetti, Francesca Colavita, Flavia Cristofanelli, Massimo Francalancia, Simona Gili, Delia Goletti, Giulia Gramigna, Germana Grassi, Daniele Lapa, Sara Leone, Davide Mariotti, Giulia Matusali, Silvia Meschi, Stefania Notari, Enzo Puro, Marika Rubino, Alessandra Sacchi, Eleonora Tartaglia, Paolo Corradini, Silvia Damian, Vincenzo Marasco, Filippo de Braud, Maria Teresa Lupo Stanghellini, Lorenzo Dagna, Francesca Rita Ogliari, Massimo Filippi (2022). Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. , 76(3), DOI: https://doi.org/10.1093/cid/ciac404.
Article11 days agoConsolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial
Pieter Sonneveld, Meletios A Dimopoulos, Meral Beksaç, Bronno van der Holt, Francesca Gay, Heinz Ludwig, Sonja Zweegman, Vladimír Maisnar, Maria Teresa Petrucci, Paolo Corradini, Fabrizio Patriarca, Angelo Belotti, Micol Quaresima, Mariella Grasso, Massimo Offidani, Laura París, Anna Marina Liberati, Markus Hansson, Heleen Visser-Wisselaar, Giulia Fumero, Renato Zambello, Paula F. Ypma, Anna Pascarella, Niels Frost Andersen, Alexandra Croockewit, Mario Boccadoro, Michèle Cavo (2024). Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-197908.
Article10 days agoOA-12 Interim Phase 2 Study Results of Durcabtagene Autoleucel (PHE885), a T-Charge™ Manufactured BCMA-Directed CAR-T Cell Therapy in Patients (pts) with r/r Multiple Myeloma (RRMM)
Andrew Spencer, Marc S. Raab, Shinsuke Iida, María-Victoria Mateos Manteca, Michèle Cavo, Paula Rodríguez‐Otero, P. Joy Ho, Yunxin Chen, Paul Ferguson, Irit Avivi, Paolo Corradini, Esther Ern‐Hwei Chan, Andy Chen, Bertrand Arnulf, Udo Holtick, Adam S. Sperling, Jufen Chu, David Pearson, Davide Germano, Ronan Feighery, Hans D. Menssen, Harald Maier, Meletios A Dimopoulos, Sagar Lonial, Nikhil Munshi (2024). OA-12 Interim Phase 2 Study Results of Durcabtagene Autoleucel (PHE885), a T-Charge™ Manufactured BCMA-Directed CAR-T Cell Therapy in Patients (pts) with r/r Multiple Myeloma (RRMM). , 24, DOI: https://doi.org/10.1016/s2152-2650(24)01853-6.
Article10 days ago